Evidence map›Paper›PMID 37847297›Full record

ArticleZeitschrift fur Rheumatologie2024

[Is JAK inhibition an option in the treatment of interstitial lung disease in rheumatoid arthritis?]

Tobias Hoffmann, Ulf Teichgräber, Bianca Lassen-Schmidt, Claus Kroegel, Martin Krämer, Martin Förster, Diane Renz, Peter Oelzner, Joachim Böttcher, Marcus Franz and 3 more

Open access · hybridAbstract readCase ReportsEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zeitschrift fur Rheumatologie, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Tobias HoffmannKlinik für Innere Medizin III, Universitätsklinikum Jena - Friedrich-Schiller-Universität Jena, Am Klinikum 1, 07747, Jena, Deutschland.
Ulf TeichgräberInstitut für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Jena - Friedrich-Schiller-Universität Jena, Am Klinikum 1, 07747, Jena, Deutschland.
Bianca Lassen-SchmidtFraunhofer Institut für Digitale Medizin MEVIS, Max-von-Laue-Str. 2, 28359, Bremen, Deutschland.
Claus KroegelKlinik für Innere Medizin I, Universitätsklinikum Jena - Friedrich-Schiller-Universität Jena, Am Klinikum 1, 07747, Jena, Deutschland.
Martin KrämerInstitut für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Jena - Friedrich-Schiller-Universität Jena, Am Klinikum 1, 07747, Jena, Deutschland.
Martin FörsterKlinik für Innere Medizin I, Universitätsklinikum Jena - Friedrich-Schiller-Universität Jena, Am Klinikum 1, 07747, Jena, Deutschland.
Diane RenzInstitut für Diagnostische und Interventionelle Radiologie, Department für Kinderradiologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.
Peter OelznerKlinik für Innere Medizin III, Universitätsklinikum Jena - Friedrich-Schiller-Universität Jena, Am Klinikum 1, 07747, Jena, Deutschland.
Joachim BöttcherKlinik für Innere Medizin III, Universitätsklinikum Jena - Friedrich-Schiller-Universität Jena, Am Klinikum 1, 07747, Jena, Deutschland.
Marcus FranzKlinik für Innere Medizin I, Universitätsklinikum Jena - Friedrich-Schiller-Universität Jena, Am Klinikum 1, 07747, Jena, Deutschland.
Gunter WolfKlinik für Innere Medizin III, Universitätsklinikum Jena - Friedrich-Schiller-Universität Jena, Am Klinikum 1, 07747, Jena, Deutschland.
Felix GüttlerInstitut für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Jena - Friedrich-Schiller-Universität Jena, Am Klinikum 1, 07747, Jena, Deutschland.
Alexander PfeilKlinik für Innere Medizin III, Universitätsklinikum Jena - Friedrich-Schiller-Universität Jena, Am Klinikum 1, 07747, Jena, Deutschland. alexander.pfeil@med.uni-jena.de.
Jena University Hospital · DEFriedrich Schiller University Jena · DEFraunhofer Institute for Digital Medicine · DEMedizinische Hochschule Hannover · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 69-year-old male patient with seropositive erosive rheumatoid arthritis (RA) presented to our clinic due to progressive dyspnea. High-resolution computed tomography (HRCT) and immunological bronchioalveolar lavage revealed ground-glass opacities and a lymphocytic alveolitis caused by interstitial lung disease (ILD) in RA. Considering previous forms of treatment, disease-modifying antirheumatic drug (DMARD) treatment was switched to tofacitinib. Tofacitinib treatment demonstrated a 33% reduction in ground-glass opacities by artificial intelligence-based quantification of pulmonary HRCT over the course of 6 months, which was associated with an improvement in dyspnea symptoms. In conclusion, tofacitinib represents an effective anti-inflammatory therapeutic option in the treatment of RA-ILD.

Indexed as

Arthritis, RheumatoidJanus Kinase InhibitorsLung Diseases, InterstitialPiperidinesPyrimidinesAgedAntirheumatic AgentsHumansMalePyrrolesTreatment OutcomeAntirheumatic AgentsJanus Kinase InhibitorsPiperidinesPyrimidinesPyrrolestofacitinibArtificial intelligence-based quantification of pulmonary high-resolution computed tomographyInterstitial lung diseaseJAK inhibitionQuantitative lung imagingRheumatoid arthritis

Identifiers

PMID37847297
PMCPMC11322242
OpenAlexW4387692285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.